Stoke Therapeutics Files for $86 Million IPO

Stoke Therapeutics filed for its IPO that could be worth up to $86 million. The Bedford, MA-based company is developing therapies to treat severe genetic diseases by, “precisely protein expression.” The filing did not include the number of shares expected to be offered. Stoke intends to trade on NASDAQ under the symbol, “STOK.”